SUSTAINED DRUG RELEASE FROM BODY IMPLANTS USING NANOPARTICLE-EMBEDDED POLYMERIC COATING MATERIALS

• US 20130004651A1
• Filed: 07/27/2012
• Published: 01/03/2013
• Est. Priority Date: 07/01/2011
• Status: Abandoned Application

• Current Assignee: Governors State University
• Original Assignee: Patty Fu-Giles
• Inventors: Fu-Giles, Patty
• Application Number:
  US13/560,730
• Publication Number:
  US 20130004651A1
• Time in Patent Office: Days
• US Class Current: 427/2.26
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/113 Multiple emulsions, e.g. oil-in-water-in-oil A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2400/12 Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 : Antibacterial agents
• CPC Class Codes: A61P 39/06 : Free radical scavengers or antioxidants

Abstract

The present invention relates to the preparation of therapeutic compositions including drug-containing nanoparticles for coating a body implant to provide for drug delivery in a locally applied and extended release manner and their methods of use to treat physiological conditions.

Claims

1. A composition comprising nanoparticles containing a therapeutically effective amount of at least one drug and a physiologically acceptable coating material whereby application of the composition to a body implant provides for extended release of the drug to treat a physiological condition.

2. The composition according to claim 1 wherein the implant comprises an ophthalmic device.

3. The composition according to claim 1 wherein the drug comprises an antibiotic selected from the group consisting of fluoroquinolone, chloramphenicol, rifampicin, vancomycin and acyclovir, including pharmacologically acceptable salts and acids thereof.

4. The composition according to claim 1 wherein the drug is selected from the group consisting of an antibiotic, a steroid, an anti-inflammatory agent, a glaucoma treatment compound, an antihistamine, a dry eye medication, a neuroprotective agent, an antineovascular agent and an antioxidant.

5. The composition according to claim 1 wherein the physiologically acceptable coating material comprises a first component selected from the group consisting of poloxamer, hydroxypropylmethyl cellulose, methylcellulose, polyvinyl alcohol and polyvinyl pyrrolidone and a second component including polycaprolactone.

6. The composition according to claim 1 wherein the implant comprises a dental implant, a cochlear implant, a nasal implant, a vascular graft, a stent and a hip, shoulder or knee replacement device.

7. The composition according to claim 1 wherein the drug comprises an antibiotic selected from the group consisting of rifampicin, chloramphenicol, novobiocin, spectinomycin, trimethoprim, erythromycin, doxycycline, minocycline, vancomycin, acyclovir, amphotericin B, gentamicin, gentamicin sulfate, tobramycin, ampicillin, penicillin, ethambutol, clindamycin, and cephalosporins including cefazolin, ceftriaxone and cefotaxime, including pharmacologically acceptable salts and acids thereof.

8. The composition according to claim 1 wherein the implant is formed of a material selected from the group consisting of polymethyl methalcrylate, hydroxyapatite, hydrogel, silicone, polytetrafluoroethylene, polyethylene, titanium, stainless steel, cobalt-chromium alloys, ceramic, titanium alloys, tantalum and zirconium alloys.

9. The composition according to claim 1 wherein the physiologically acceptable coating material comprises a first component selected from the group consisting of polyvinylpyrrolidone, polymethylmethacrylate isobutene mono-isopropylmaleate, hexamethyldisiloxane and isooctane solvent-based siloxane polymers and copolymers thereof admixed with a second component selected from the group consisting of nitrocellulose, 2-octyl cyanoacrylate and n-butyl cyanoacrylate.

10. A method for the sustained release of a drug from a physiologically acceptable coating material applied to a body implant comprising:

a) encapsulating the drug into nanoparticles;

b) incorporating the nanoparticles into the physiologically acceptable coating material to form a nanoparticle-embedded polymeric coating material; and

c) applying the product of step b to the implant before surgery

whereby the drug is released from the implants over an extended period of time to treat a physiological condition.

11. The method according to claim 10 wherein the implant comprises an ophthalmic device.

12. The method according to claim 10 wherein the drug comprises an antibiotic selected from the group consisting of fluoroquinolone, chloramphenicol, rifampicin, vancomycin and acyclovir, including pharmacologically acceptable salts and acids thereof.

13. The method according to claim 10 wherein the drug is selected from the group consisting of an antibiotic, a steroid, an anti-inflammatory agent, a glaucoma treatment compound, an antihistamine, a dry eye medication, a neuroprotective agent, an antineovascular agent and an antioxidant.

14. The method according to claim 10 wherein the physiologically acceptable coating material comprises a first component selected from the group consisting of poloxamer, hydroxypropylmethyl cellulose, methylcellulose, polyvinyl alcohol and polyvinyl pyrrolidone and a second component including polycaprolactone.

15. The method according to claim 10 wherein the implant comprises a dental implant, a cochlear implant, a nasal implant, a vascular graft, a stent and a hip, shoulder or knee replacement device.

16. The method according to claim 10 wherein the drug comprises an antibiotic selected from the group consisting of rifampicin, chloramphenicol, novobiocin, spectinomycin, trimethoprim, erythromycin, doxycycline, minocycline, vancomycin, acyclovir, amphotericin B, gentamicin, gentamicin sulfate, tobramycin, ampicillin, penicillin, ethambutol, clindamycin, and cephalosporins including cefazolin, ceftriaxone and cefotaxime, including pharmacologically acceptable salts and acids thereof.

17. The method according to claim 10 wherein the implant is formed of a material selected from the group consisting of polymethyl methalcrylate, hydroxyapatite, hydrogel, silicone, polytetrafluoroethylene, polyethylene, titanium, stainless steel, cobalt-chromium alloys, ceramic, titanium alloys, tantalum and zirconium alloys.

18. The method according to claim 10 wherein the physiologically acceptable coating material comprises a first component selected from the group consisting of polyvinylpyrrolidone, polymethylmethacrylate isobutene mono-isopropylmaleate, hexamethyldisiloxane and isooctane solvent-based siloxane polymers and copolymers thereof admixed with a second component selected from the group consisting of nitrocellulose, 2-octyl cyanoacrylate and n-butyl cyanoacrylate.